{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052055","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.442923+00:00","generated_at":"2026-06-03T00:50:20.001117+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monte Rosa CSO Owen Wallace departs May 17 to become CEO at UK biotech; remains adviser","bullets":["Owen Wallace resigns as CSO effective May 17, 2024, to become CEO of a UK-based biotech company.","Departure is not due to any disagreement with Monte Rosa or its board; will continue as scientific adviser on SAB.","Drug discovery led by Sharon Towson (CTO), John Castle (CDIO), and Magnus Walter (SVP Drug Discovery).","Company expects no disruption to ongoing MGD programs or drug discovery efforts."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052055","json":"https://secwatch.observer/filing/0000950170-24-052055.json","markdown":"https://secwatch.observer/filing/0000950170-24-052055.md","text":"https://secwatch.observer/filing/0000950170-24-052055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024052055/0000950170-24-052055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024052055/glue-20240429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:50:20.001117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6fb6f087c","claim":"Owen Wallace resigned as Chief Scientific Officer at Monte Rosa Therapeutics, Inc..","evidence_excerpt":"On April 29, 2024, Owen Wallace, the Chief Scientific Officer of Monte Rosa Therapeutics, Inc. (the \"Company\"), resigned from the Company effective May 17, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024052055/0000950170-24-052055-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}